FORA vs HCAT vs HIMS vs INFU vs OPRX vs JPM vs KO

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus 1. 5% for Health Catalyst, Inc. (HCAT). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 2x trailing P/E (14. 6x forward), making it the more compelling value choice. Analysts rate Health Catalyst, Inc. (HCAT) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 2x versus Hims & Hers Health, Inc. at 69. 5x. On forward P/E, OptimizeRx Corporation is actually cheaper at 5. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 83x versus The Coca-Cola Company's 2. 17x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +219. 5%, compared to -96. 8% for Health Catalyst, Inc. (HCAT). Over 10 years, the gap is even starker: JPM returned +481. 2% versus HCAT's -95. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

23β versus Hims & Hers Health, Inc. 's 2. 53β — meaning HIMS is approximately -1184% more volatile than KO relative to the S&P 500. On balance sheet safety, Forian Inc. (FORA) carries a lower debt/equity ratio of 0% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus 1. 5% for Health Catalyst, Inc. (HCAT). On earnings-per-share growth, the picture is similar: InfuSystem Holdings, Inc. grew EPS 181. 8% year-over-year, compared to -121. 7% for Health Catalyst, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -57. 2% for Health Catalyst, Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -11. 6% for HCAT. At the gross margin level — before operating expenses — HIMS leads at 73. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 83x versus The Coca-Cola Company's 2. 17x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 5. 3x forward P/E versus 44. 8x for Health Catalyst, Inc. — 39. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 241. 4% to $17. 00.

In this comparison, KO (2.

6% yield), JPM (1. 8% yield) pay a dividend. FORA, HCAT, HIMS, INFU, OPRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

23), 2. 6% yield, +115. 0% 10Y return). OptimizeRx Corporation (OPRX) carries a higher beta of 2. 16 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +115. 0%, OPRX: +53. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (FORA (Healthcare) and HCAT (Healthcare) and HIMS (Healthcare) and INFU (Healthcare) and OPRX (Healthcare) and JPM (Financial Services) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: FORA is a small-cap high-growth stock; HCAT is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; INFU is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock; JPM is a large-cap deep-value stock; KO is a large-cap quality compounder stock. JPM, KO pay a dividend while FORA, HCAT, HIMS, INFU, OPRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.